Lenz
8 known investors
LENZ Therapeutics is a pharmaceutical company that develops and commercializes VIZZ (aceclidine ophthalmologic solution 1.44%), an FDA-approved eye drop for treating presbyopia, the age-related loss of near vision. The product targets patients seeking an alternative to reading glasses.
Founders & leadership
ES
Eef Schimmelpenninkin
Investors · 8
Alpha Wave GlobalMiami
RA CapitalBoston
Raptor GroupMiami Beachvia James J. Pallotta · inferred
RTW Investments L.P.reportedNew York
Sectoral Asset ManagementreportedMontreal
Versant VenturesreportedSan Francisco · $250K – $5M
Also in the syndicate · 2
Alpha Wave VenturesPoint 72
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BMar 2023
Sectoral Asset Management (lead), Alpha Wave Ventures, Point 72, RA Capital Management, RTW Investments, Versant Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Lenz do?
- LENZ Therapeutics is a pharmaceutical company that develops and commercializes VIZZ (aceclidine ophthalmologic solution 1.44%), an FDA-approved eye drop for treating presbyopia, the age-related loss of near vision. The product targets patients seeking an alternative to reading glasses.
- Who are Lenz's investors?
- Lenz's investors include Alpha Wave Global, RA Capital, Raptor Group, RTW Investments L.P., Sectoral Asset Management, Versant Ventures.